证券代码：002287 证券简称：奇正藏药 编号：2020-003 西藏奇正藏药股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------------|--------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 中信证券资管 | 蔡霁磊 金鹰基金 蒋婉莹 | | 人员姓名 | 辰悦资本 周易 | 华能信托 张国平 | | | 合众资管 金妍 | 康曼德资本 丁楹 | | | 诚信人寿 谭丁源 | 方正证券 卢克楠 | | | 中金资管 李楠 | 华实浩瑞 王聪 | | | 益民基金 张树声 | | | 时间 | 2020 年 10 月 23 | 日 10:00-11:30 | | 地点 | 北京市西城区太平桥大街 ...

证券代码：002287 证券简称：奇正藏药 编号：2020-004 西藏奇正藏药股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-----------------------------------|------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 □分析师会议 | | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 （请文字说明其他活动内容） | | | 参与单位名称及 | 汇添富基金 吴君 睿郡资产 丁晨霞 | | | 人员姓名 | 太平洋资产 李鸣 凯石基金 盛夏 | | | | 中山证券 顾明豪 万联证券 姚文 | | | | | 聚鸣投资 王广群 胡宏亮 西部利得 冯浩琪 | | | 兴全基金 朱喆丰 申万菱信 杨扬 | | | 时间 | 2020 年 10 月 26 日 | 10:00-11:30 | | 地点 | 上海市徐汇区长乐路 | 989 号 ...

股票代码：002287 股票简称：奇正藏药 债券代码：128133 债券简称：奇正转债 西藏奇正藏药股份有限公司 投资者关系活动记录表 编号：2022-006 | --- | --- | --- | |---------------------|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动类 别 | √特定对象调研 \n□新闻发布会 □路演活动 \n□现场参观 □其他（请文字说明其他活动内容） | □分析师会议 \n□媒体采访 □业绩说明会 | | 活动参与人员 | 平安证券：叶寅、韩盟盟 奇正藏药：冯平、李阳、陈宏艳 | | | 时间 | 2022 年 11 月 24 日 | 9:30-10:30 | | 地 ...

股票代码：002287 股票简称：奇正藏药 债券代码：128133 债券简称：奇正转债 西藏奇正藏药股份有限公司投资者关系活动记录表 编号：2021-003 | --- | --- | --- | --- | |-------------------------|---------------------------------------------|------------------------------------------------------------------------------------|------------| | | | | | | 投资者关系活动类 | | √特定对象调研 □分析师会议 | | | 别 | □媒体采访 | □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | | □现场参观 | | | | | □其他 | （请文字说明其他活动内容） | | | 参与单位名称及人 员姓名 | | 国信证券金融市场总部固定收益投资部 朱张元 | | | 时间 | 2021 年 11 月 5 日 | 13:30-14:30 | | | 地点 | 腾讯会议 | ...

股票代码：002287 股票简称：奇正藏药 债券代码：128133 债券简称：奇正转债 西藏奇正藏药股份有限公司投资者关系活动记录表 编号：2021-004 | --- | --- | --- | --- | --- | |------------------|-------------------------------|--------------------------------------------------|-------|-------| | | | | | | | 投资者关系活动类 | √特定对象调研 □分析师会议 | | | | | 别 | □媒体采访 | □业绩说明会 | | | | | □新闻发布会 □路演活动 | | | | | | □现场参观 | | | | | | □其他 | （请文字说明其他活动内容） | | | | 参与单位名称及人 | 西南证券 杜向阳 阮雯 | | | | | 员姓名 | 永赢基金 李松 陆凯琳 | | | | | 时间 | 2021 年 12 月 14 日 | 13:30-14:30 | | | | 地点 | 腾讯会议 | | | | | 上市公司接待 ...

股票代码：002287 股票简称：奇正藏药 债券代码：128133 债券简称：奇正转债 西藏奇正藏药股份有限公司投资者关系活动记录表 编号：2021-005 | --- | --- | --- | --- | --- | |------------------|-------------------------------|---------------------------------------------------|-------|----------| | | | | | | | 投资者关系活动类 | √特定对象调研 □分析师会议 | | | | | 别 | □媒体采访 | □业绩说明会 | | | | | □新闻发布会 □路演活动 | | | | | | □现场参观 | | | | | | □其他 | （请文字说明其他活动内容） | | | | 参与单位名称及人 | 国盛证券 胡偌碧、杨春雨 | | | | | 员姓名 | 泰康资产 | 颜媛、王晓锋、周颖辉、闵锐、王宇行 | | | | 时间 | 2021 年 12 月 20 日 | 13:30-15:00 | | | | 地点 | 腾讯会议 ...

股票代码：002287 股票简称：奇正藏药 债券代码：128133 债券简称：奇正转债 西藏奇正藏药股份有限公司 投资者关系活动记录表 编号：2022-002 | --- | --- | --- | --- | --- | --- | --- | |--------------------|------------------------------------------------------|-------------------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | √特定对象调研 □分析师会议 | | | | | | | | □媒体采访 | □业绩说明会 | | | | | | 投资者关系活动类别 | □新闻发布会 □路演活动 □现场参观 | | | | | | | | □其他（请文字说明其他活动内容） | | | | | | | 活动参与人员 | 天风证券 张文星 华夏基金 章心玥 易方达 王蕾 | | | | | | | ...

股票代码：002287 股票简称：奇正藏药 债券代码：128133 债券简称：奇正转债 西藏奇正藏药股份有限公司 投资者关系活动记录表 编号：2022-001 | --- | --- | --- | |--------------------|---------------------------------------------------------------------------------|----------------------------------------------------| | 投资者关系活动类别 | □媒体采访 \n□新闻发布会 □路演活动 □现场参观 \n□其他（请文字说明其他活动内容） | √特定对象调研 □分析师会议 \n□业绩说明会 | | | 民生医药 宋丽莹 | | | 活动参与人员 | 财通资管 冯雪云 奇正藏药 冯平 李阳 | | | 时间 | 2022 年 5 月 10 日 | 9:30-10:30 | | 地点 | 腾讯会议 | | | 形式 | 线上会议 | | | | | 一、介绍藏医药及公司基本情况 | | | 1 | 、藏医学——来自雪域高原的 ...

股票代码：002287 股票简称：奇正藏药 债券代码：128133 债券简称：奇正转债 西藏奇正藏药股份有限公司 投资者关系活动记录表 编号：2022-005 | --- | --- | --- | |---------------------|----------------------------------------------------------------------------------|--------------------------------------------------------| | | | | | | √特定对象调研 | □分析师会议 | | | □媒体采访 □业绩说明会 | | | 投资者关系活动类 别 | □新闻发布会 □路演活动 | | | | □现场参观 □其他（请文字说明其他活动内容） | | | 活动参与人员 | 易方达基金：王元春、余欣鑫 东方证券：刘恩阳、马宝云、易丹阳 奇正藏药：冯平、李阳 | | | 时间 | 2022 年 11 月 11 日 | 9:30-10:30 | | 地点 | 腾讯会议 | | | 形式 | 线上会议 | | | | 一 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥519,212,989.60, representing a year-on-year increase of 28.89%[5] - Net profit attributable to shareholders for the same period was ¥127,221,135.64, a significant increase of 137.34% compared to the previous year[5] - The net profit after deducting non-recurring gains and losses was ¥126,907,331.26, up by 63.37% year-on-year[5] - Basic earnings per share for Q3 2022 were ¥0.2407, an increase of 137.24% compared to the same period last year[5] - Net profit for the current period was ¥357,525,838.41, a decrease from ¥645,927,284.24, reflecting a decline of approximately 44.5%[29] - Basic earnings per share were CNY 0.6784, down from CNY 1.2247 in the previous period[32] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,457,758,867.56, a decrease of 1.98% from the end of the previous year[5] - The total assets decreased to ¥5,457,758,867.56 from ¥5,567,753,848.57, a reduction of about 2%[25] - Current liabilities totaled ¥1,084,226,284.39, down from ¥1,307,979,313.93, showing a decrease of approximately 17%[25] - Non-current liabilities increased to ¥1,105,008,433.53 from ¥1,039,391,910.81, marking an increase of about 6.3%[25] - The total equity attributable to shareholders of the parent company increased to ¥3,216,024,928.04 from ¥3,169,030,586.36, showing a growth of approximately 1.5%[25] Cash Flow - The company's cash flow from operating activities showed a significant decline, with a net amount of ¥192,374,939.97, down by 66.32% year-on-year[5] - Net cash flow from operating activities decreased by 66.32% to $192.37 million, primarily due to reduced cash received from sales and increased cash payments for employee compensation[14] - Cash inflow from operating activities totaled CNY 1,351,313,488.40, a decrease of 236,727,728.06 from CNY 1,588,041,216.46 in the previous period[33] - Net cash flow from operating activities was CNY 192,374,939.97, significantly lower than CNY 571,227,074.26 in the previous period[35] - Cash outflow from investing activities was CNY 1,397,190,085.90, compared to CNY 2,752,828,076.34 in the previous period[35] - Net cash flow from investing activities improved by 80.99% to -$279.09 million, as cash used for purchasing wealth management products decreased[14] - Cash flow from financing activities resulted in a net outflow of -CNY 399,891,357.86, compared to -CNY 207,157,680.76 in the previous period[35] Investment and Expenses - The company recognized an investment loss of ¥75,006,700.00 from its participation in a merger fund during the reporting period[9] - The financial expenses increased by 171.03% to ¥30,399,841.09 due to reduced interest income and increased loan interest[11] - The company's investment income decreased by 120.85% to -$60.75 million due to reduced long-term equity investment returns and wealth management product investment income[14] - The company reported a significant decline in investment income, with a loss of ¥60,752,497.46 compared to a gain of ¥291,417,294.11 in the previous period[29] - Research and development expenses for the current period were ¥46,893,261.76, compared to ¥44,393,885.66 in the previous period, reflecting an increase of approximately 5.6%[26] Shareholder Information - The total number of common shareholders at the end of the reporting period was 25,144, with the largest shareholder holding 68.75% of the shares[15] - Minority interests loss increased by 37.97% to -$2.02 million, indicating higher losses from controlled subsidiaries[14] Other Financial Metrics - The weighted average return on equity was 4.40%, reflecting a decrease of 13.85% year-on-year[5] - The company reported a loss of ¥40,062.14 from the disposal of non-current assets during the reporting period[6] - Total operating revenue for the current period reached ¥1,416,132,351.38, an increase from ¥1,189,266,190.30 in the previous period, representing a growth of approximately 19.1%[26] - Total operating costs amounted to ¥1,004,641,422.30, up from ¥844,453,879.84, indicating a rise of about 18.9%[26] - Total comprehensive income for the period amounted to CNY 361,177,638.72, a decrease of 645,729,862.64 compared to the previous period[32] - The company's cash and cash equivalents decreased significantly, impacting liquidity and operational flexibility[25] - The ending balance of cash and cash equivalents was CNY 183,676,142.50, down from CNY 726,006,732.94 in the previous period[35] Audit Information - The company did not undergo an audit for the third quarter report[37]